BMS-986012, an Anti–Fucosyl-GM1 Monoclonal Antibody as Monotherapy or in Combination With Nivolumab in Relapsed/Refractory SCLC: Results From a First-in-Human Phase 1/2 Study - Concepedia

Concepedia

Publication | Open Access

BMS-986012, an Anti–Fucosyl-GM1 Monoclonal Antibody as Monotherapy or in Combination With Nivolumab in Relapsed/Refractory SCLC: Results From a First-in-Human Phase 1/2 Study

DOI Full Paper Access

16

Citations

19

References

2022

Year

Quincy S. Chu, Natasha B. Leighl, Veerle Surmont, Carla van Herpen, Anne Sibille, Ben Markman, Stephen Clarke, Rosalyn A. Juergens, Mirelis Acosta Rivera, Vladimir Andelkovic,

JTO Clinical and Research Reports

References

	Year	Citations

Page 1